Skip to main content
SpringerLink
Log in

Pulmonale Hypertonie

Neuartiges Fusionsprotein senkt den pulmonal-vaskulären Widerstand

  • Journalclub
  • Published:
Pneumo News Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Atkinson C, Stewart S, Upton PD et al. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation. 2002;105(14):1672-8

  2. Farber HW, Miller DP, Poms AD et al. Five-Year outcomes of patients enrolled in the REVEAL Registry. Chest. 2015;148(4):1043-54

Download references

Author information

Authors and Affiliations

  1. Zentrum für Pneumologie und Thoraxchirurgie, Asklepios Fachkliniken München-Gauting, Robert-Koch-Allee 2, 82131, Gauting, Germany

    Christopher Breyer

Authors
  1. Christopher Breyer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christopher Breyer.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Breyer, C. Neuartiges Fusionsprotein senkt den pulmonal-vaskulären Widerstand. Pneumo News 13, 20–21 (2021). https://doi.org/10.1007/s15033-021-2755-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15033-021-2755-3

Search

Navigation